Clinical Comparison of Whole-Body Radioiodine Scan and Serum Thyroglobulin After Stimulation with Recombinant Human Thyrotropin
Explore this paper's citation graph
Summary
It is shown that rhTSH-stimulated WBS and Tg are complementary, but Tg is a more sensitive indicator of disease recurrence or persistence than rhTSH-stimulated Tg.
- Type
- article
- Published
- 2002-01-01
- Cited by
- 105
- References
- 38
- OpenAlex
- https://openalex.org/W1968467130
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:45321855
Keywords
Medicine, Thyroglobulin, Internal medicine, Thyroid cancer, Thyroid
References
- Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
- Serum thyroglobulin measurement. Utility in clinical practice.
- Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
- Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
- Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels.
- SERIAL SERUM THYROGLOBULIN MEASUREMENTS IN THE MANAGEMENT OF DIFFERENTIATED THYROID CARCINOMA
- SERUM THYROGLOBULIN CONCENTRATIONS AND 131I WHOLE BODY SCANS IN THE DIAGNOSIS OF METASTASES FROM DIFFERENTIATED THYROID CARCINOMA (AFTER THYROIDECTOMY)
- Elevated serum thyroglobulin. A marker of metastases in differentiated thyroid carcinomas.
- Quality-of-Life Changes in Patients with Thyroid Cancer After Withdrawal of Thyroid Hormone Therapy
- Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer.
- [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
- Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma.
- The comparative value of serum thyroglobulin measurements and iodine 131 total body scans in the follow-up study of patients with treated differentiated thyroid cancer.
- The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels
- Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer.
- Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
- Strategies for Thyrotropin Use to Monitor Patients with Treated Thyroid Carcinoma
- Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma
- Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans
- Using Recombinant Human TSH in the Management of Well-Differentiated Thyroid Cancer: Current Strategies and Future Directions
Cited by
- Preoperative determination of serum thyroglobulin to identify patients with differentiated thyroid cancer who may present recurrence without increased thyroglobulin.
- La stratégie d'utilisation de la scintigraphie corporelle à l'iode : intérêt de l'iode 123.
- Recombinant Human Thyrotropin (rhTSH) in the Follow-Up and Treatment of Patients with Thyroid Cancer
- Thyroglobulin: current status in differentiated thyroid carcinoma (review).
- Recommendations for post-surgical thyroid ablation in differentiated thyroid cancer: a 2015 position statement of the Italian Society of Endocrinology
- NEW DEVELOPMENTS IN THE DIAGNOSIS AND TREATMENT OF THYROID CANCER
- Papillary and follicular thyroid cancers in children.
- The Cut-Off Level of Recombinant Human TSH-Stimulated Thyroglobulin in the Follow-Up of Patients with Differentiated Thyroid Cancer
- rhTSH stimulation before radioiodine therapy in thyroid cancer reduces the effective half-life of (131)I.
- Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection
- Guidelines for the management of thyroid cancer
- A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma.
- Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients.
- Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer.
- Sequential Follow-up of Serum Thyroglobulin and Whole Body Scan in Thyroid Cancer Patients without Initial Metastasis
- Management of differentiated thyroid carcinoma with radioiodine and recombinant human TSH.
- Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer
- Papillary thyroid cancer: Medical management and follow-up
- Radioiodine treatment in pediatric Graves disease and thyroid carcinoma
- Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized Study
Related papers
- Serum thyroglobulin in the management of patients with thyroid cancer.
- Effect of Antithyroglobulin Antibody on Thyroglobulin About Differentiated Thyroid Cancer Patients
- The Role of Routine Diagnostic Radioiodine Whole-Body Scintigraphy in Patients with High-Risk Differentiated Thyroid Cancer
- [The use of 131I in the combined modality therapy of highly differentiated cancer of the thyroid gland].
- Utility of Stimulated Thyroglobulin in Reclassifying Low Risk Thyroid Cancer Patients’ Following Thyroidectomy and Radioactive Iodine Ablation: A 7-Year Prospective Trial
- Modern Management of Differentiated Thyroid Cancer
- Radioactive Iodine Therapy in Differentiated Thyroid Cancer: 2020 Update.
- Urinary Exosomal Thyroglobulin in Thyroid Cancer Patients With Post-ablative Therapy: A New Biomarker in Thyroid Cancer
- Low Serum Thyroglobulin at Time of Radioablation of Differentiated Thyroid Cancer Is a Good Predictor for No Recurrence
- The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy